Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

By Goldstein Barry J.   Weissman Peter N.   Wooddell Margaret J.   Waterhouse Brian R.   Cobitz Alexander R.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1715-1723

Informa Healthcare

Access to resources Recommend Favorite

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 689-698

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double‐blinded placebo‐controlled study

By  

PEDIATRIC DIABETES (ELECTRONIC), Vol. 16, Iss. 3, 2015-05 ,pp. : 196-203

John Wiley & Sons Inc

Access to resources Recommend Favorite

Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 4, 2015-04 ,pp. : 409-414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study

By  

DIABETIC MEDICINE, Vol. 32, Iss. 11, 2015-11 ,pp. : 1460-1469

John Wiley & Sons Inc

Access to resources Recommend Favorite